Amundi Pioneer Asset Management Inc. Decreases Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)
Amundi Pioneer Asset Management Inc. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 95,572 shares of the biopharmaceutical company’s stock after selling 51,622 shares during the quarter. Amundi Pioneer Asset Management Inc. owned about 0.10% of Alnylam Pharmaceuticals worth $11,229,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. QS Investors LLC boosted its holdings in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth $221,000. Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $229,000. Finally, Fayerweather Charles purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $230,000. Hedge funds and other institutional investors own 88.43% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $134.54 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. During the same period in the prior year, the company posted ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.
A number of equities analysts have recently commented on ALNY shares. Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an “equal weight” rating in a report on Thursday, November 9th. Cowen reissued a “buy” rating and set a $151.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, November 9th. Credit Suisse Group increased their price objective on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Needham & Company LLC reiterated a “buy” rating and set a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Finally, J P Morgan Chase & Co raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $121.85.
In other news, Director Dennis A. Ausiello sold 20,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total value of $2,600,000.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at approximately $2,600,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 73,415 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the completion of the transaction, the chief executive officer now owns 223,125 shares of the company’s stock, valued at approximately $29,207,062.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 363,212 shares of company stock worth $44,032,736. Insiders own 4.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/01/amundi-pioneer-asset-management-inc-decreases-holdings-in-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.